Table 3.
Safety and efficacy outcomes.
| Analysis | Definite or Probable ST | MI | Cardiac Death | All-Cause Death | TLR | TVR |
|---|---|---|---|---|---|---|
| Outcomes at longest follow-up | 0.94 (0.62–1.43) | 1.06 (0.85–1.33) | 0.98 (0.80–1.21) | 0.87 (0.76–1.00) | 1.12 (0.94–1.33) | 1.18 (0.87–1.61) |
| Outcomes at 1 year | 1.38 (0.56–3.43) | 1.12 (0.68–1.85) | 1.08 (0.50–2.32) | 0.87 (0.48–1.60) | 1.04 (0.65–1.67) | 2.00 (0.51–7.85) |
| Outcomes at 2 years | 0.85 (0.39–1.82) | 1.06 (0.64–1.73) | 0.88 (0.36–2.16) | 0.82 (0.52–1.29) | 1.81 (0.89–3.68) | 1.52 (0.75–3.08) |
| Outcomes at 5 years | 0.91 (0.50–1.69) | 0.96 (0.70–1.32) | 1.01 (0.79–1.28) | 0.90 (0.77–1.06) | 1.02 (0.85–1.21) | 1.00 (0.87–1.15) |
| Landmark analysis beyond 1 year | 0.34 (0.01–8.20) | 0.44 (0.13–3.50) | 0.46 (0.24–81.57) | 0.85 (0.45–1.62) | 1.09 (0.51–2.33) | 1.07 (0.43–2.66) |
| Subgroup analysis | ||||||
| PF-DES anti-proliferative drug | ||||||
| Amphilimus | 1.42 (0.54–3.73) | 1.12 (0.67–1.87) | 1.15 (0.52–2.54) | 0.90 (0.49–1.67) | 1.00 (0.60–1.65) | 2.00 (0.51–7.85) |
| Biolimus | NR | 1.23 (0.25–6.15) | 5.46 (0.31–97.06) | 1.48 (0.50–4.38) | 1.15 (0.46–2.84) | 1.31 (0.65–2.64) |
| Paclitaxel | 0.97 (0.35–2.70) | 1.12 (0.43–2.87) | 0.81 (0.33–2.00) | 0.84 (0.37–1.90) | *2.32 (1.30–4.14) | 1.61 (0.55–4.71) |
| Sirolimus | 0.67 (0.17–2.60) | 1.52 (0.92–2.50) | 0.86 (0.52–1.42) | 0.84 (0.59–1.21) | 1.09 (0.81–1.46) | 0.85 (0.55–1.34) |
| Sirolimus/Probucol | 0.85 (0.47–1.52) | 0.90 (0.66–1.22) | 1.00 (0.78–1.29) | 0.87 (0.74–1.02) | 1.02 (0.84–1.23) | 1.01 (0.87–1.17) |
| DP-DES anti-proliferative drug | ||||||
| Everolimus | NR | 0.33 (0.01–8.01) | 3.00 (0.12–72.10) | NR | NR | NR |
| Paclitaxel | 0.77 (0.17–3.55) | 1.43 (0.75–2.72) | 0.97 (0.54–1.74) | 0.75 (0.48–1.19) | 1.29 (0.76–2.20) | 1.93 (0.23–3.02) |
| Sirolimus | 0.81 (0.38–1.72) | 1.03 (0.62–1.71) | 0.80 (0.31–2.07) | 0.80 (0.51–1.27) | 1.30 (0.80–2.14) | 0.86 (0.32–2.34) |
| Zotarolimus | 1.01 (0.59–1.72) | 0.99 (0.74–1.33) | 1.00 (0.79–1.28) | 0.88 (0.75–1.03) | 1.02 (0.85–1.23) | 1.01 (0.87–1.17) |
| Generation of DP-DES | ||||||
| First-generation | 0.85 (0.44–1.64) | 1.19 (0.83–1.69) | 0.91 (0.59–1.39) | 0.86 (0.65–1.14) | 1.23 (0.93–1.64) | 1.29 (0.83–2.02) |
| Second-generation | 1.01 (0.59–1.72) | 0.98 (0.73–1.32) | 1.01 (0.80–1.28) | 0.88 (0.75–1.03) | 1.02 (0.85–1.23) | 1.01 (0.87–1.17) |
| Duration of DAPT | ||||||
| 6 months | 0.85 (0.48–1.53) | 1.01 (0.75–1.38) | 0.99 (0.79–1.25) | 0.86 (0.74–1.00) | 1.18 (0.87–1.60) | 1.48 (0.87–2.51) |
| 12 months | 1.04 (0.57–1.91) | 1.12 (0.80–1.56) | 0.94 (0.57–1.56) | 0.94 (0.69–1.30) | 1.12 (0.81–1.57) | 0.86 (0.57–1.29) |
Values are risk ratio (95% confidence interval); MI = myocardial infarction; NR = not reported; PF-DES = polymer-free drug-eluting stents; TLR = target lesion revascularization; TVR = target vessel revascularization; ST = stent thrombosis; * = statistical significance (P < 0.05).